200 related articles for article (PubMed ID: 34092621)
1. Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy.
Cao Y; Li Q; Liu H; He X; Huang F; Wang Y
Cancer Biomark; 2021; 32(2):237-248. PubMed ID: 34092621
[TBL] [Abstract][Full Text] [Related]
2. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
4. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
5. Tim-3 finds its place in the cancer immunotherapy landscape.
Acharya N; Sabatos-Peyton C; Anderson AC
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601081
[TBL] [Abstract][Full Text] [Related]
6. Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer.
Lu X
Curr Med Chem; 2022; 29(11):1851-1865. PubMed ID: 34365943
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
8. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
[TBL] [Abstract][Full Text] [Related]
9. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Du W; Yang M; Turner A; Xu C; Ferris RL; Huang J; Kane LP; Lu B
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28300768
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
[TBL] [Abstract][Full Text] [Related]
11. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy.
Yang R; Hung MC
Sci China Life Sci; 2017 Oct; 60(10):1058-1064. PubMed ID: 29027155
[TBL] [Abstract][Full Text] [Related]
12. Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential.
Saleh R; Toor SM; Elkord E
Expert Opin Ther Targets; 2020 Dec; 24(12):1251-1262. PubMed ID: 33103506
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy.
Wu M; Wu A; Zhang X; Li Y; Li B; Jin S; Dong Q; Niu X; Zhang L; Zhou X; Du J; Wu Y; Zhai W; Zhou X; Qiu L; Gao Y; Zhao W
Biochem Pharmacol; 2023 Jun; 212():115583. PubMed ID: 37148978
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation.
Dixon KO; Tabaka M; Schramm MA; Xiao S; Tang R; Dionne D; Anderson AC; Rozenblatt-Rosen O; Regev A; Kuchroo VK
Nature; 2021 Jul; 595(7865):101-106. PubMed ID: 34108686
[TBL] [Abstract][Full Text] [Related]
16. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
17. Expansion of dysfunctional Tim-3-expressing effector memory CD8+ T cells during simian immunodeficiency virus infection in rhesus macaques.
Fujita T; Burwitz BJ; Chew GM; Reed JS; Pathak R; Seger E; Clayton KL; Rini JM; Ostrowski MA; Ishii N; Kuroda MJ; Hansen SG; Sacha JB; Ndhlovu LC
J Immunol; 2014 Dec; 193(11):5576-83. PubMed ID: 25348621
[TBL] [Abstract][Full Text] [Related]
18. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
19. Role of TIM-3 in ovarian cancer.
Xu Y; Zhang H; Huang Y; Rui X; Zheng F
Clin Transl Oncol; 2017 Sep; 19(9):1079-1083. PubMed ID: 28357631
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
Kim KJ; Lee HW; Seong J
J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]